Interference with pathways activated by topoisomerase inhibition alters the surface expression of PD‑L1 and MHC I in colon cancer cells
Open Access
- 9 December 2022
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 25 (1) , 1-11
Abstract
Topoisomerase inhibitors are clinically used to treat various cancer types, including colorectal cancer. These drugs also activate signaling pathways that modulate cell survival and immune cell functions. Immunotherapy is promising for certain tumors, including microsatellite instable colorectal cancer, but not for microsatellite stable colorectal cancer. The reasons for this lack of responsiveness are largely unknown. Understanding how colorectal cancer cell‑surface proteins interact with tumor‑resident immune cells may offer an opportunity to identify molecules that, if targeted, may render tumor cells visible to immune cells. The present study used flow cytometry, fluorescent staining and immunoblotting to examine if inhibition of pathways activated by topoisomerase‑targeting drugs may modulate the outcomes of treatment through effects on cell cycle arrest and apoptosis, and by altering surface expression levels of programmed death‑ligand 1 (PD‑L1) or major histocompatibility complex protein I (MHC I). Inhibition of either NF‑κB or DNA‑damage response (DDR) potently enhanced cell death in combination with topoisomerase inhibition, while only NF‑κB inhibition increased MHC I. PD‑L1 upregulation was moderately affected by NF‑κB or DDR inhibitors, while both topoisomerase inhibitors and DNA damaging agents may enhance the surface expression of MHC I molecules on colon cancer cells. Such enhanced expression of MHC I may be suppressed by inhibitors of ataxia‑telangiectasia mutated or checkpoint kinase kinases. Additionally, adaptive tolerance to topoisomerase inhibition caused altered cell cycle response, and reduced the expression levels of both PD‑L1 and MHC I on both microsatellite instable and stable colon cancer cell lines. Therefore, targeted modulation of DDR pathways, PD‑L1, MHC I or other immune regulators in colon cancer cells may make them more visible to immune cells and enable rational combination of conventional therapy with immunotherapy.Keywords
This publication has 38 references indexed in Scilit:
- Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer CellsPLOS ONE, 2012
- Radiation-Triggered NF-κB Activation is Responsible for the Angiogenic Signaling Pathway and Neovascularization for Breast Cancer Cell Proliferation and GrowthBreast Cancer: Basic and Clinical Research, 2012
- ATR: a master conductor of cellular responses to DNA replication stressTrends in Biochemical Sciences, 2011
- High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patientsInternational Journal of Cancer, 2010
- Cell Survival from Chemotherapy Depends on NF-κB Transcriptional Up-Regulation of Coenzyme Q BiosynthesisPLOS ONE, 2009
- Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor InhibitionCancer Research, 2009
- Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal CancerJournal of Clinical Oncology, 2009
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosisMolecular Immunology, 2008
- ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA DamageScience, 2007
- NF-κB Activation by CamptothecinJournal of Biological Chemistry, 2000